ES2477877T3 - Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos - Google Patents

Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos Download PDF

Info

Publication number
ES2477877T3
ES2477877T3 ES08785441.0T ES08785441T ES2477877T3 ES 2477877 T3 ES2477877 T3 ES 2477877T3 ES 08785441 T ES08785441 T ES 08785441T ES 2477877 T3 ES2477877 T3 ES 2477877T3
Authority
ES
Spain
Prior art keywords
hydroxy vitamin
mammals
muscle mass
increase muscle
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08785441.0T
Other languages
English (en)
Other versions
ES2477877T5 (es
Inventor
Thau Kiong Chung
Benito Averion Oliveros
Francisco Feranil Penalba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39874890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2477877(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of ES2477877T3 publication Critical patent/ES2477877T3/es
Application granted granted Critical
Publication of ES2477877T5 publication Critical patent/ES2477877T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de 25-hidroxi vitamina D3 para promover de forma no terapéutica la miogénesis en un mamífero al administrar de forma prenatal una cantidad suficiente de 25-hidroxi vitamina D3 al mamífero durante el período de hiperplasia de fibras musculares.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES08785441.0T 2007-08-07 2008-08-07 Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos Active ES2477877T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07015458 2007-08-07
EP07015458 2007-08-07
PCT/EP2008/006537 WO2009019027A1 (en) 2007-08-07 2008-08-07 Use of 25-hydroxy vitamin d3 to increase muscle mass in mammals

Publications (2)

Publication Number Publication Date
ES2477877T3 true ES2477877T3 (es) 2014-07-18
ES2477877T5 ES2477877T5 (es) 2018-09-21

Family

ID=39874890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08785441.0T Active ES2477877T5 (es) 2007-08-07 2008-08-07 Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos

Country Status (9)

Country Link
US (1) US20110124608A1 (es)
EP (1) EP2173356B2 (es)
JP (1) JP5509502B2 (es)
KR (1) KR101503948B1 (es)
CN (1) CN101778636B (es)
DK (1) DK2173356T4 (es)
ES (1) ES2477877T5 (es)
PL (1) PL2173356T5 (es)
WO (1) WO2009019027A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2440206T3 (en) * 2009-06-11 2018-11-05 Dsm Ip Assets Bv Trigonellin as a muscle stimulant
CN107232417B (zh) * 2017-06-28 2018-09-25 广西商大科技股份有限公司 一种母猪六段式营养全价饲料和投料方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
EP1516540B1 (en) * 2003-09-22 2012-09-26 DSM IP Assets B.V. Use of vitamin D compounds
KR20080039420A (ko) * 2005-08-18 2008-05-07 디에스엠 아이피 어셋츠 비.브이. 수컷 동물의 번식력을 향상시키는데 있어서의25-하이드록시 비타민 디3의 용도
CA2624897C (en) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
US8685949B2 (en) * 2005-11-25 2014-04-01 Dsm Ip Assets B.V. Use of 25-hydroxy vitamin D3 to improve vitality of animals

Also Published As

Publication number Publication date
EP2173356B2 (en) 2018-05-02
CN101778636B (zh) 2012-11-28
PL2173356T5 (pl) 2018-11-30
DK2173356T3 (da) 2014-07-07
ES2477877T5 (es) 2018-09-21
EP2173356B1 (en) 2014-04-16
DK2173356T4 (en) 2018-08-13
PL2173356T3 (pl) 2014-09-30
WO2009019027A1 (en) 2009-02-12
EP2173356A1 (en) 2010-04-14
JP2010535727A (ja) 2010-11-25
KR20100053549A (ko) 2010-05-20
CN101778636A (zh) 2010-07-14
KR101503948B1 (ko) 2015-03-18
JP5509502B2 (ja) 2014-06-04
US20110124608A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
IT1392903B1 (it) Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
AR062857A1 (es) Crema para bebidas
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
ES2526913T3 (es) Composición farmacéutica que contiene neurotoxina 2 botulínica
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
BRPI0815821A2 (pt) Composições e métodos que empregam antagonistas nmda para alcançar um efeito poupador de anestésico.
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
ES2517491T3 (es) Estabilizador de los vasos linfáticos
PA8534101A1 (es) Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa
AR050903A1 (es) Metodo para la prevencion de trastornos tromboticos, embolicos y/o hemorragicos
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
ES2477877T3 (es) Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos
AR074302A1 (es) Trans-clomifeno para el sindrome metabolico y la diabetes mellitus tipo 2.. metodo
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
ITMI20051446A1 (it) Composizione per ridurre i lipid nel sangue
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
AR062784A1 (es) Tratmiento de los vertigos con acetil -l- leucina
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado